Pinar Saip

Pinar Saip

Auto-generated profile, based on publicly available information

Pinar Saip

Department of Medical Oncology Istanbul University Institute of Oncology Istanbul Turkey

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
ECEngin Celik
Engin Celik
IYInci Kizildag Yirgin
Inci Kizildag Yirgin
HCHale Goksever Celik
Hale Goksever Celik
GEGulgun Engin
Gulgun Engin
HSHamdullah Sozen
Hamdullah Sozen
MSMehmet Y. Salihoglu
Mehmet Y. Salihoglu

1 September 2011 in Oncology
Verified
Journal Article
Closed access
SKSerkan Keskin
Serkan Keskin
MMMahmut Muslumanoglu
Mahmut Muslumanoglu
PSPinar Saip
Pinar Saip
HKHasan Karanlık
Hasan Karanlık
MGMurat Guveli
Murat Guveli
ETErkan Topuz
Erkan Topuz
Objective: Patients with breast cancer with a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) have a better prognosis than patients with residual disease. The aim of the current study was to identify predictors of pCR. Methods: This retrospective study included 388 patients treated with anthracycline-based NAC. Clinicopathological parameters were compared between the patients with and without pCR in breast and axilla. Results: Treatment consisted of FAC/FEC in 230 patients (59%), TAC in 39 (10%) patients and AC followed by docetaxel in 119 (31%). In all, 36 (9.3%) patients had pCR. In univariate analysis, age, tumor size, lymph node involvement, tumor grade (p = 0.077, n = 265), ER and HER-2 status (n = 213), lymphovascular invasion (LVI), type of chemotherapy and taxane-containing chemotherapy were associated with pCR. In multivariate analysis, ER negativity (p = 0.003), the absence of LVI (p = 0.009) and taxane-containing NAC (p = 0.026) were found to be significant indicators of pCR. Median follow-up time was 69 months. Progression-free survival was significantly improved in patients achieving pCR (p = 0.001). Conclusions: pCR is associated with a better outcome regardless of clinical and pathological parameters in breast cancer patients who receive NAC. The probability of pCR was higher in ER-negative, LVI-negative tumors and in patients treated with sequential taxane-containing chemotherapy.

7 June 2021 in Cancer Investigation
Verified
Journal Article
Closed access
ABAykut Bahçeci
Aykut Bahçeci
SPSemra Paydas
Semra Paydas
NANaziye Ak
Naziye Ak
FFFerhat Ferhatoğlu
Ferhat Ferhatoğlu
PSPınar Mualla Saip
Pınar Mualla Saip
NYNilgün Yildirim
Nilgün Yildirim
The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Retrospective analysis o...

16 May 2018 in European Journal of Breast Health
Verified
Journal Article
Closed access
HYHulya Yazici
Hulya Yazici
SKSeda Kılıç
Seda Kılıç
DADemet Akdeniz
Demet Akdeniz
OEOzge Sukruoglu Erdogan
Ozge Sukruoglu Erdogan
STSeref Bugra Tuncer
Seref Bugra Tuncer
PSPinar Saip
Pinar Saip
Eur J Breast Health AVES | Copyright © 2017 Türkiye Meme Hastalıkları Dernekleri Federasyonu |

31 May 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IDIzzet Dogan
Izzet Dogan
EAEsra Aydin
Esra Aydin
NKNijat Khanmammadov
Nijat Khanmammadov
NPNail Paksoy
Nail Paksoy
PSPinar Saip
Pinar Saip
AAAdnan Aydiner
Adnan Aydiner
The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer patients who received long-term trastuzumab were included in the study. Predictors of complete response were analyzed with binary regression analysis. The prognosis of patients who had their trastuzumab-based treatment terminated was assessed. Eighty patients were involved in the study. The patients were received with trastuzumab for a median of 62 months (12–191). A complete response was observed in 60 (75%) patients. The median duration to development of complete response was found as 14.8 months (2.4–55). In logistic regression analysis: using endocrine therapy with trastuzumab (p = 0.04), menopausal status (p = 0.03), and the number of metastatic sites (p = 0.01) were found to be statistically significant factors for a complete response. Trastuzumab-based therapy of fifteen patients was terminated, six (40%) patients continued to receive an aromatase inhibitor, and nine (60%) patients were followed up without treatment. After termination of trastuzumab, at a median follow-up of 32 months (11–66), recurrence was detected in two (13.3%) patients. We detected that menopausal status, the number of metastatic sites, and using endocrine therapy with trastuzumab were predictors of complete response in HER2-positive metastatic breast cancer patients who received long-term trastuzumab-based therapy. We observed that HER2-positive metastatic breast cancer patients may be completely cured with trastuzumab-based therapy. There are no defined criteria for termination of trastuzumab treatment in this selected patient group. It is necessary to confirm our data with multicenter studies involving a large number of patients.

3 February 2022 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
DODemet Akdeniz Odemis
Demet Akdeniz Odemis
BCBetul Celik
Betul Celik
SKSeda Kılıç
Seda Kılıç
OEOzge Sukruoglu Erdogan
Ozge Sukruoglu Erdogan
STSeref Bugra Tuncer
Seref Bugra Tuncer
HYHulya Yazici
Hulya Yazici
Objectives: To find BRCA1/2 test selection criteria unique to the Turkish population, as well as to provide the BRCA1/2 gene mutation distributions of patient population to the literature. Methods: Genetic counseling was given to 2,373 cases with a family history of high-risk breast and/or ovarian cancer who applied to Istanbul University, Oncology Institute, Department of Cancer Genetics between 1994 and 2021 and selected by NCCN Guidelines for the BRCA1/2 test criteria. In our clinic, mutation screenings in BRCA1/2 genes were performed by Sanger sequencing method in patients admitted between 1994 and 2014 and by NGS method in patients admitted between 2015 and 2021. Results: The overall mutation rate in our patient group selected from high-risk patients was 16.5% (391/2,373) after BRCA1/2 gene mutation screening performed in 2,373 cases who applied to the Cancer Genetics clinic. Of the patients with mutations, 57.5% (225/391) had BRCA1 mutation, 41.9% (164/391) had BRCA2 mutation, and 0.6% (2/391) had both BRCA1 and BRCA2 pathogenic mutations. People diagnosed before the age of 60 who have a history of triple-negative breast cancer had a 28.5% overall mutation rate. Conclusions: BRCA1/2 mutation in Turkish population were evaluated in accordance with NCCN BRCA1/2 genetic test selection criteria; we discovered that all of our study results were statistically significant (p<0.05).